These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23968624)

  • 21. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States.
    Alghanem N; Abokwidir M; Fleischer AB; Feldman SR; Alghanem W
    J Dermatolog Treat; 2017 Mar; 28(2):119-128. PubMed ID: 27241622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International prices and availability of pharmaceuticals in 2005.
    Danzon PM; Furukawa MF
    Health Aff (Millwood); 2008; 27(1):221-33. PubMed ID: 18180499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How cheap are Canada's drugs really?
    Hollis A
    J Pharm Pharm Sci; 2004 Jun; 7(2):215-6. PubMed ID: 15367378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Availability, prices and affordability of essential medicines in Zhejiang Province, China.
    Dong Z; Tao Q; Yan B; Sun G
    PLoS One; 2020; 15(11):e0241761. PubMed ID: 33232336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International comparison of generic medicine prices.
    Simoens S
    Curr Med Res Opin; 2007 Nov; 23(11):2647-54. PubMed ID: 17877848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.